Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
response rate in overall skin disease
over the course of study
Judy H Chiao, M.D.
Cyclacel Pharmaceuticals, Inc.
United States: Food and Drug Administration
|The University of Texas MD Anderson Cancer Center||Houston, Texas 77030-4009|
|Stanford University Hospitals and Clinics||Stanford, California 94305|
|Timothy Kuzel, M.D.||Chicago, Illinois 60611|